Brief: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval To Continue With Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH

MetaVia

13/03/2024 12:14

March 13 (Reuters) - Neurobo Pharmaceuticals Inc
 NRBO.O :
    * NEUROBO PHARMACEUTICALS RECEIVES SAFETY REVIEW COMMITTEE
APPROVAL TO CONTINUE WITH ITS PHASE 2A CLINICAL TRIAL EVALUATING
DA-1241 FOR THE TREATMENT OF MASH
    * NEUROBO PHARMACEUTICALS INC -FULL DATA READOUT EXPECTED IN
SECOND HALF OF 2024
    * NEUROBO PHARMACEUTICALS INC - BLINDED SAFETY REVIEW
COMPLETED
FOR FIRST 6 MONTHS OF PHASE 2A CLINICAL TRIAL CONDUCT
    * NEUROBO PHARMACEUTICALS INC -  SRC RECOMMENDING TRIAL
CONTINUE
WITHOUT MODIFICATION

Source text for Eikon:  ID:nPn83F9hra 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))